Organogenesis Holdings ( (ORGO) ) has released its Q2 earnings. Here is a breakdown of the information Organogenesis Holdings presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and commercializes products for advanced wound care and surgical and sports medicine markets.
In the second quarter of 2025, Organogenesis Holdings reported a net product revenue of $100.8 million, reflecting a decline from the previous year, while also reducing its net loss compared to the same period in 2024.
The company experienced a 25% decrease in revenue from its Advanced Wound Care products, while revenue from Surgical & Sports Medicine products saw a 16% increase. Despite these mixed results, the net loss decreased to $9.4 million from $17.0 million in the previous year. Operating expenses were reduced by 21%, contributing to a smaller operating loss.
Looking forward, Organogenesis Holdings anticipates policy changes in 2026 that could stabilize the industry and create new opportunities. The company remains committed to its leadership in regenerative medicine and is optimistic about the potential of its product, ReNu, for knee osteoarthritis.